Biotech Values

[zipjet]

EXEL

I listened shortly after the call so my memory may be fading.

But I seem to recall the investigator saying that no agent up to now has shown activity in BOTH the soft tumors and the bone mets.

XL184 reduced pain (a critical problem) and appears (dramatic changes in the slides) to be reversing bone mets (skeletal failure is the main cause of death in fast moving PC).

The results were not semantics even if trial design was.

PC is the #2 cancer-killer of males (behind lung cancer). There are around 70K new cases per year of the fast moving variety. This is a big unmet medical need.

ij